Trials / Recruiting
RecruitingNCT06736613
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
Cerebral Spinal Fluid Circulating Tumor DNA (ctDNA) Analysis in Patients With Aggressive B-cell Lymphoma Receiving Front Line Therapy and at High Risk for Central Nervous System Relapse
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out how many people with B-cell lymphoma who are at high risk for central nervous system/CNS relapse test positive for cerebral spinal fluid/CSF ctDNA but test negative for CNS involvement using standard tests. The study will also look at how often CNS relapse happens in people with and without detected CSF ctDNA.
Conditions
- Diffuse Large B Cell Lymphoma
- High-grade B-cell Lymphoma
- Stage III High Grade B-Cell Lymphoma
- Stage IV High Grade B-Cell Lymphoma
- DLBCL - Diffuse Large B Cell Lymphoma
- Intravascular Large B-Cell Lymphoma
- Diffuse Large B Cell Lymphoma of Breast
- Diffuse Large B Cell Lymphoma of Testis
- HIV-associated Diffuse Large B Cell Lymphoma
- Double Expressor DLBCL
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Cerebral Spinal Fluid ctDNA | MSK's Diagnostic Molecular Pathology core has developed and validated a CSF ctDNA assay which has been approved by New York State Department of Health as of 2019 |
Timeline
- Start date
- 2024-12-11
- Primary completion
- 2027-12-11
- Completion
- 2027-12-11
- First posted
- 2024-12-17
- Last updated
- 2025-12-18
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06736613. Inclusion in this directory is not an endorsement.